Patrys Limited, a biopharmaceutical company, develops products for the treatment of cancer in Australia. The company develops PAT-SM6, a natural human antibody that is in Phase I/IIa clinical trials used for the treatment of various types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers, such as multiple myeloma; and PAT-SC1, a clinical trial antibody that treats gastric cancer. It also develops PAT-LM1, a natural human antibody that is used for the treatment of colon, lung, breast, ovary, and pancreatic cancers; and Deoxymab 3E10, a lupus autoantibody that penetrates live cell nuclei by binding to DNA or its precursors outside of cells and then following it into cell nuclei through a nucleoside transporter. The company was founded in 2006 and is based in South Melbourne, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 9692 7222
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$514,365.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Patrys (ASX:PAB) Frequently Asked Questions
What is Patrys' stock symbol?
Patrys trades on the ASX under the ticker symbol "PAB."
Has Patrys been receiving favorable news coverage?
News coverage about PAB stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Patrys earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Patrys.
Who are some of Patrys' key competitors?
Some companies that are related to Patrys include Pharmaxis (PXS), Allergy Therapeutics (AGY), Futura Medical (FUM), Vita Life Sciences (VLS), Cathay International (CTI), Recce Pharmaceuticals (RCE), Avivagen (VIV), Antisense Therapeutics (ANP), NanoViricides (NNVC), Sareum (SAR), China Pharma (CPHI), N4 Pharma (N4P), Bayer (BAYN), HedgePath Pharmaceuticals (MAYNF) and OTSUKA HOLDINGS/ADR (OTSKY).
Who are Patrys' key executives?
Patrys' management team includes the folowing people:
- Dr. James A. Campbell Ph.D., MBA, MD, CEO & Director
- Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Company Sec. (Age 46)
- Dr. Deanne Greenwood GAICD, Ph.D., MBA, VP of Bus. Devel. & Intellectual Property
What is Patrys' stock price today?
One share of PAB stock can currently be purchased for approximately A$0.03.
How big of a company is Patrys?
What is Patrys' official website?
How can I contact Patrys?
The company can be reached via phone at 61 3 9692 7222.
MarketBeat Community Rating for Patrys (ASX PAB)
MarketBeat's community ratings are surveys of what our community members think about Patrys and other stocks. Vote "Outperform" if you believe PAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
